Lv11
90 积分 2024-11-05 加入
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
6小时前
已完结
Rounding rituximab dose to nearest vial size
1个月前
已完结
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
1个月前
已完结
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
1个月前
已完结
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study
1个月前
已完结
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
1个月前
已完结
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia
2个月前
已完结
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
2个月前
已完结
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy
2个月前
已关闭
Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia
5个月前
已完结
皖公网安备34019202002308
